Free Trial
NASDAQ:CDLX

Cardlytics (CDLX) Stock Price, News & Analysis

$3.83
-0.09 (-2.30%)
(As of 10/23/2024 ET)

About Cardlytics Stock (NASDAQ:CDLX)

Key Stats

Today's Range
$3.69
$4.00
50-Day Range
$3.06
$4.08
52-Week Range
$2.89
$20.52
Volume
1.02 million shs
Average Volume
1.25 million shs
Market Capitalization
$186.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.92
Consensus Rating
Reduce

Company Overview

Cardlytics, Inc. operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing. The company was incorporated in 2008 and is headquartered in Atlanta, Georgia.

Cardlytics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
77th Percentile Overall Score

CDLX MarketRank™: 

Cardlytics scored higher than 77% of companies evaluated by MarketBeat, and ranked 83rd out of 333 stocks in the business services sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cardlytics has received a consensus rating of Reduce. The company's average rating score is 1.86, and is based on no buy ratings, 6 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Cardlytics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Cardlytics' stock forecast and price target.
  • Earnings Growth

    Earnings for Cardlytics are expected to remain at ($1.72) per share in the coming year.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cardlytics is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cardlytics is -1.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cardlytics has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Cardlytics' valuation and earnings.
  • Percentage of Shares Shorted

    16.99% of the outstanding shares of Cardlytics have been sold short.
  • Short Interest Ratio / Days to Cover

    Cardlytics has a short interest ratio ("days to cover") of 7.1.
  • Change versus previous month

    Short interest in Cardlytics has recently increased by 0.36%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Cardlytics does not currently pay a dividend.

  • Dividend Growth

    Cardlytics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.99% of the outstanding shares of Cardlytics have been sold short.
  • Short Interest Ratio / Days to Cover

    Cardlytics has a short interest ratio ("days to cover") of 7.1.
  • Change versus previous month

    Short interest in Cardlytics has recently increased by 0.36%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Cardlytics has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Business Services companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Cardlytics this week, compared to 3 articles on an average week.
  • MarketBeat Follows

    3 people have added Cardlytics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cardlytics insiders have sold 82.37% more of their company's stock than they have bought. Specifically, they have bought $143,200.00 in company stock and sold $261,149.00 in company stock.

  • Percentage Held by Insiders

    Only 4.40% of the stock of Cardlytics is held by insiders.

  • Percentage Held by Institutions

    68.10% of the stock of Cardlytics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cardlytics' insider trading history.
Receive CDLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardlytics and its competitors with MarketBeat's FREE daily newsletter.

CDLX Stock News Headlines

Watch this before it gets removed
If you missed it, my emergency election broadcast is now available - but will be removed soon
Evercore ISI Begins Coverage on Cardlytics (NASDAQ:CDLX)
See More Headlines

CDLX Stock Analysis - Frequently Asked Questions

Cardlytics' stock was trading at $9.21 at the beginning of 2024. Since then, CDLX stock has decreased by 58.4% and is now trading at $3.83.
View the best growth stocks for 2024 here
.

Cardlytics, Inc. (NASDAQ:CDLX) announced its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.12. The company's quarterly revenue was down 9.2% compared to the same quarter last year.

Cardlytics subsidiaries include Bridg, DOSH, Cardlytics Services India Private Limited, and Cardlytics UK Limited.

Cardlytics (CDLX) raised $76 million in an initial public offering on Friday, February 9th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan served as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

Cardlytics' top institutional shareholders include Creative Planning (0.06%), SG Americas Securities LLC (0.03%) and Shikiar Asset Management Inc. (0.02%). Insiders that own company stock include Clifford Sosin, Karim Saad Temsamani, Lynne Marie Laube, Scott D Grimes, Amit Gupta, Alexis Desieno, Nicholas Hollmeyer Lynton, Andrew Christiansen, John V Balen and Kirk Somers.
View institutional ownership trends
.

Shares of CDLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cardlytics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), Intel (INTC) and Rambus (RMBS).

Company Calendar

Last Earnings
8/07/2024
Today
10/23/2024
Next Earnings (Estimated)
11/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Computer programming, data processing, & other computer related
Sub-Industry
Computer Software
Current Symbol
NASDAQ:CDLX
Fax
N/A
Employees
457
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$6.92
High Stock Price Target
$12.00
Low Stock Price Target
$3.50
Potential Upside/Downside
+80.6%
Consensus Rating
Reduce
Rating Score (0-4)
1.86
Research Coverage
7 Analysts

Profitability

Net Income
$-134,700,000.00
Pretax Margin
-50.21%

Debt

Sales & Book Value

Annual Sales
$305.42 million
Cash Flow
$1.47 per share
Book Value
$3.43 per share

Miscellaneous

Free Float
47,647,000
Market Cap
$186.84 million
Optionable
Optionable
Beta
1.67

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (NASDAQ:CDLX) was last updated on 10/24/2024 by MarketBeat.com Staff
From Our Partners